Growth in a life sciences organization rarely happens in a perfectly controlled sequence.
Teams expand. Programs advance. New suppliers and service providers have been introduced. Responsibilities shift. Operations have become more complex. Clinical programs progress toward commercialization.
But the Quality Management System (QMS) does not always evolve at the same pace.
A QMS that worked well for an early-stage organization may be incomplete as the organization grows. Procedures may no longer reflect how work is actually performed. Responsibilities can become unclear. Deviations may increase and cause procedures to be Frankenstein together. Supplier oversight may struggle to keep pace. Quality activities can become increasingly reactive.
These situations do not necessarily indicate that the QMS has failed. They may indicate that the organization has simply outgrown the system it originally built.
What Does It Mean to Outgrow a QMS?
A pharmaceutical quality system provides a framework for managing product quality throughout the product lifecycle. ICH Q10 describes a model for an effective pharmaceutical quality system and emphasizes lifecycle management, management responsibility, continual improvement, knowledge management, and quality risk management.[1] FDA has similarly described a comprehensive Quality Systems model intended to support modern quality systems and risk-management approaches while maintaining compliance with CGMP requirements.[2]
The appropriate Quality infrastructure of an organization may therefore evolve as its operations, products, risks, and regulatory responsibilities change.
An early-stage company may operate effectively with a relatively lean QMS, limited procedures, a small supplier network, and Quality responsibilities concentrated among a few individuals. As the organization grows, that same structure may need to support additional employees and departments, increased manufacturing or clinical activity, more complex supplier relationships, additional products or programs, increased documentation volume, more quality events, expanded training requirements, and preparation for regulatory inspections or commercialization.
The broader principle is important: a Quality System should not remain static while the organization around it continues to evolve. Remember, continuous improvement also applies to our documentation system.
1. Procedures No Longer Reflect Actual Operations
One warning sign is a growing difference between written procedures and how work is actually performed. Employees may begin relying on institutional knowledge, informal instructions, workarounds, or interpretations that are not clearly reflected within approved procedures.
FDA’s CGMP framework requires appropriate written procedures and controls for pharmaceutical manufacturing operations, while its Quality Systems guidance describes documentation as an important element of an effective quality system.[2][3]
When controlled procedures consistently lag behind actual operations, organizations should evaluate whether documentation and change-management processes remain appropriate for their current environment.
2. Quality Responsibilities Have Become Unclear
Growth often introduces new functions, roles, vendors, and management structures. Responsibilities that were straightforward when the organization was smaller can become increasingly difficult to define.
Questions may begin to arise: Who owns the investigation? Who approves this supplier? Who follows up on this CAPA? Who evaluates the Quality impact of a change? Who monitors supplier performance?
ICH Q10 places significant emphasis on management responsibility and defined roles within the pharmaceutical quality system.[1] As an organization expands, periodically reassessing process ownership, Quality responsibilities, and decision-making authority can help ensure the QMS continues to reflect how the organization actually operates.
3. Deviations or Investigations Are Increasing
An increase in deviations does not automatically mean that a Quality System is ineffective. However, trends matter.
Repeated deviations, recurring investigations, increasing investigation timelines, or similar events occurring across multiple departments may indicate an opportunity to evaluate the broader system rather than viewing each event independently.
ICH Q10 identifies the Corrective Action and Preventive Action system as a key element of the pharmaceutical quality system and describes investigation and root-cause approaches as part of structured improvement.[1] Organizations should therefore consider not only individual events, but also what aggregate Quality data may reveal about process performance and recurring risks.
4. CAPAs Are Closing, but Problems Keep Returning
CAPA performance should not be evaluated solely by the number of records closed. A CAPA may reach administrative closure while the underlying issue continues to occur.
Recurring issues may warrant additional evaluation of root cause analysis, corrective-action design, implementation, effectiveness verification, or broader system controls. The objective is not simply closure. The objective is effective improvement and reduction of recurrence.[1]
5. Supplier Oversight Is Becoming Difficult to Manage
Supplier networks often expand rapidly as organizations grow. New laboratories, manufacturers, raw-material suppliers, consultants, logistics providers, and other service providers may be introduced to support expanding operations.
FDA’s Quality Agreements guidance explains how parties involved in contract drug manufacturing can define and document manufacturing activities and CGMP responsibilities.[4] ICH Q10 also addresses oversight of outsourced activities and purchased materials within the pharmaceutical quality system.[1]
As supplier networks become more complex, organizations may encounter inconsistent qualification practices, outdated risk classifications, delayed audits, incomplete Quality Agreements, limited supplier performance monitoring, unclear ownership, or qualification documentation gaps.
ICH Q9(R1) provides a framework for Quality Risk Management and emphasizes science-based, risk-based decision-making.[5] As the supplier network grows, maintaining a structured, risk-based approach becomes increasingly important.
6. Change Control Becomes Primarily Reactive
Growth creates change. Organizations introduce new equipment, processes, systems, facilities, suppliers, documents, technologies, and responsibilities.
Change management is specifically incorporated into the ICH Q10 pharmaceutical quality system model.[1] A mature change-management process should enable proposed changes to be evaluated before implementation, including consideration of potential Quality impacts and appropriate risk management.
Depending on the change, this may involve evaluating affected systems and documents, training requirements, validation activities, regulatory considerations, supplier impacts, and implementation requirements. FDA’s Quality Agreements guidance also addresses change-control responsibilities in contract manufacturing relationships.[4]
If change controls are routinely initiated late, remain open for extended periods, or function primarily as documentation after decisions have already been implemented, organizations should consider whether the process is still serving its intended purpose.
7. Inspection Readiness Becomes an Event
Focused preparation before an inspection is normal. However, if inspection readiness repeatedly requires a major last-minute remediation effort, it may be useful to evaluate whether underlying Quality processes are functioning effectively during normal operations.
FDA’s Quality Systems approach emphasizes modern quality systems and risk-management approaches that support ongoing CGMP compliance.[2] Inspection readiness is strongest when it reflects the organization’s normal state of control rather than a temporary condition created immediately before an inspection.
What Should Organizations Do When These Signs Appear?
The solution is not necessarily to create more procedures. Adding unnecessary complexity can create additional administrative burden without addressing the underlying problem.
Instead, organizations can begin by understanding where the existing system may no longer adequately support current operations, risks, and regulatory responsibilities. A structured QMS assessment may consider governance and Quality responsibilities, document management, training, deviations and investigations, CAPA, change management, Supplier Quality, Quality Risk Management, internal audits, Quality metrics, validation, and inspection readiness.
ICH Q9(R1) provides principles and tools for Quality Risk Management that can support risk-based decision-making across these areas.[5] The objective should be to identify meaningful gaps, understand their potential impact, and determine which improvements warrant priority.
Avoid the Temptation to Fix Everything at Once
Not every gap presents the same level of risk. ICH Q9(R1) states that evaluation of risk to quality should be based on scientific knowledge and ultimately linked to patient protection, and that the level of effort, formality, and documentation should be commensurate with the level of risk.[5]
A risk-based remediation strategy may therefore consider potential impact to patient safety, product quality, data integrity, regulatory compliance, operational risk, recurrence, and business continuity.
Higher-risk weaknesses can receive appropriate attention while lower-risk improvements are incorporated into a longer-term Quality roadmap. This allows the QMS to evolve deliberately rather than through a series of disconnected reactions.
A Scalable QMS Should Grow With the Organization
An effective QMS should provide appropriate control without creating unnecessary complexity.
The goal is not to build the largest Quality System possible. It is to build the right Quality System for the organization’s current stage, activities, risks, and regulatory responsibilities, while creating a framework capable of evolving as the organization continues to grow.
ICH Q10 is structured around the pharmaceutical product lifecycle and continual improvement, reinforcing the concept that the Quality System should support changing needs throughout the lifecycle.[1]
When External Quality Support May Help
Organizations may consider external Quality support, like BlueTide when internal teams are managing significant growth, preparing for regulatory milestones, addressing recurring Quality issues, expanding supplier networks, or attempting to remediate multiple QMS gaps simultaneously.
An independent assessment can provide an additional perspective on how procedures, responsibilities, Quality events, supplier controls, and operational practices interact across the organization.
External support does not transfer an organization’s regulatory responsibilities to a consultant or contractor. FDA’s Quality Agreements guidance makes clear that statutory and regulatory CGMP responsibilities cannot simply be delegated through a Quality Agreement.[4]
The objective of external support should be to help the organization strengthen its own Quality System, identify risks, establish priorities, and develop sustainable controls.
How BlueTide Quality Partners Can Support Your Organization
BlueTide Quality Partners supports life sciences organizations in developing, assessing, and strengthening Quality Management Systems that are practical, scalable, and aligned with the needs of the business.
Our support includes QMS development and remediation, gap assessments, procedure and policy development, Supplier Quality and vendor oversight, deviation and CAPA support, Quality Risk Management, inspection readiness, and broader Quality Systems consulting.
Whether your organization is establishing its first formal Quality infrastructure or reassessing a system that has become increasingly difficult to manage, our team can help identify risks, establish priorities, and develop a practical path forward.
Is your QMS keeping pace with your organization?
Connect with us on LinkedIn | Contact: [email protected]
References
1. ICH Q10: Pharmaceutical Quality System (FDA, April 2009)
3. FDA: Current Good Manufacturing Practice (CGMP) Regulations
4. FDA: Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016)
5. ICH Q9(R1): Quality Risk Management (FDA, May 2023)